**Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secon
Endpoints in Acute Bacterial Skin Infections**

Omadacycline generally safe and well tolerated
Company on track to file NDAs with FDA as early as 1Q 2018
Webcast and conference call for investors at 4:30 p.m. today EDT to review top-line results

BOSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced toc pivotal Phase 3 clinical study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice of acute bacterial skin and skin structure infections (ABSSSI). The study met all of its primary and secondary approval for this indication by the U.S. Food and Drug Administration (FDA) and the European Medicines Age positive Phase 3 registration study of omadacycline.

"This successful study demonstrates the potential of an oral-only dosing regimen of omadacycline, which w outpatient setting and potentially reduce the need for admission to the hospital," said Michael Bigham, Chair Paratek. "The utility of the oral only dosing regimen represents a significant potential benefit to patients and effective oral agents to combat serious community-acquired infections."

The pivotal Phase 3 clinical study known as OASIS-2 (Omadacycline in Acute Skin Structure Infections Study once-daily, oral-only omadacycline compared to twice-daily, oral-only linezolid in 735 adults with ABSSSI. O primary endpoint of statistical non-inferiority (NI) in the modified intent-to-treat (mITT) population (10% NI m compared to linezolid at the early clinical response (ECR), 48 to 72 hours after the first dose of study drug. T 87.5% compared to 82.5% for linezolid.

Additionally, omadacycline met statistical NI compared to linezolid for the EMA-specified co-primary endpoi (PTE), 7 to 14 days after completion of therapy in the mITT and the Clinically Evaluable (CE) populations. Cli population for the omadacycline and linezolid arms were 84.2% vs. 80.8%, respectively; and in the CE popula respectively.

Omadacycline demonstrated high clinical success rates for infections caused by the most common ABSSSI resistant Staphylococcus aureus (MRSA).

In the OASIS-2 study, there was a low rate of study treatment discontinuation for both omadacycline and line respectively. Less than 2% of patients discontinued treatment due to adverse events in both treatment group omadacycline treatment arm. The most common treatment emergent adverse events (TEAEs) in omadacycl nausea (30.2% vs. 7.6%, respectively) and vomiting (16.8% vs. 3.0%, respectively). Seventy-five percent of th none reported as severe, and only one omadacycline patient discontinued treatment for gastrointestinal eve the nausea or vomiting in omadacycline patients occurred during the loading-dose phase on day 1 or day 2, a episodes was two days. Additional TEAEs, occurring in ≥ 3% of omadacycline patients were increased alanin increased aspartate aminotransferase (AST; 4.6%), diarrhea (4.1%) and headache (3.5%), which were genera arms. No subject in either treatment group developed *Clostridium difficile* infection.

"We are excited by the outstanding efficacy observed in our oral-only skin study, which is consistent with the OASIS-1 and OPTIC studies," said Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Office adverse event rates were higher in this study than in OASIS-1; however, these events were generally mild an efficacy rates were very high in this study, confirming the utility of the oral-only omadacycline regimen and c omadacycline for ABSSSI and CABP."

The results of this study, including the results of the secondary endpoints, will be presented at an upcoming

Conference Call and Webcast
The Company will host a webcast and conference call for investors at 4:30 p.m. ET today. The live webcast c Presentations" in the Investor Relations section of Paratek's website at www.paratekpharma.com (https://w data=CgivLk07ObQR9wPErBOEDd1UlWQ38TrZDR9R_UOXGCsoXRAp6T5FMv5F1MYJ3RijYk_jsm_F-pTWnC

The webcast can also be accessed at this link http://public.viavid.com/index.php?id=125259 (https://www.gl
data=Mq9W4fubh2EM1aj1X7CYZ3ERlrkf9DuWecV7kDR6JMTtfZC1MhVgLRwY-kkZlaDb8rFTErLuljmmZ--
jPre6u9C_d-wdF2thnpAIc_g9DiUMXS3Mitx6PcW7UBdqqDll7AlJwaL_IrGyQ7QOOZ_AYA==). The webcast w

Domestic callers wishing to participate in the call should dial 877-407-0792 and international callers should
call will be available until July 31, 2017. Using the same conference ID, replays can be accessed by domesti
International callers should dial 412-317-6671. The replay PIN is 13665829.

About the OASIS-2 Study Design
The OASIS-2 study was a randomized, double-blind, multi-center study that enrolled 735 adult subjects with
centers in the U.S. Patients received either once daily omadacycline or twice daily linezolid for 7-14 days. In a
against the FDA- and EMA-specified primary endpoints, the study comprised other efficacy outcome measur
resolution or improvement of signs and symptoms. In addition, safety and tolerability were assessed by treat
sign measurements, ECGs and laboratory values.

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercia
upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, if approv
tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-neg
Omadacycline is a new, once-daily oral and intravenous broad-spectrum antibiotic being developed for use a
suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structu
bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly
concern to prescribing physicians. Omadacycline has been granted Qualified Infectious Disease Product desi
U.S. Food and Drug Administration for the target indications.

In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skir
(OASIS-1) demonstrating the efficacy and general safety and tolerability of intravenous (IV) to once-daily ora
linezolid. In April 2017, Paratek announced positive efficacy data in a Phase 3 registration study in communit
(OPTIC) demonstrating the efficacy and general safety and tolerability of IV to once-daily oral omadacycline
Company plans to submit its NDAs in the U.S. as early as the first quarter of 2018 with an EMA submission la

In addition to its Phase 3 program for omadacycline, in November 2016 Paratek reported positive top-line PK
study in uncomplicated urinary tract infections (UTI). The Company plans to begin enrolling patients in a pro
omadacycline in UTI as early as December 2017.

In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore t
pathogenic agents causing infectious diseases of public health and biodefense importance including plague a

In April 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the Company, and Zai Lab (Shanghai) Co.,
Collaboration Agreement. Under the terms of the Agreement, the Company granted Zai an exclusive license
commercialize omadacycline in the People's Republic of China, Hong Kong, Macau and Taiwan, for all humar
other than biodefense.

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily oral, narrow-spectr
potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community settin
the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan and Parat
identical Phase 3 registration studies of sarecycline for the treatment of moderate to severe acne vulgaris in
announced plans to submit an NDA in the U.S. in the second half of 2017.

For more information, visit www.paratekpharma.com (https://www.globenewswire.com/Tracker?
data=CgivLk07ObQR9wPErBOEDd1UlWQ38TrZDR9R_UOXGCuU_2nu4RV23OCHwn_IdcGc-
Qph_m02gd2mJd3R0yEM8j3JLfzkZzrkJZXpvXt47NAIwryRHK9NGZ_JDMf6gYhZyOUwWWMn8vVa3g-
cECNwTMXyquK05T0vgoU1G9BNnXJA9x0k8E_CI0MGV3EoBekRmVwLJUXVIMIQQusJVj2ej8QJmcK0mwY

dnkmtmBzbKLIXTWdpkf1HR_Abty3VwhUKaa_NiezISKlSpl9fWDIgD9U78EdCTk28SEk_HhCrEiMZAWpu_G9/
jyuGgC9ac_J0phEdvAR-RA5EMTHEHvOgkJUyX5JF11pJ0orJ2uhW_dHzKjYQEXfDO6fpc0r4uJQLv0QIGqZ3
QJbkn6hxJJUUSp8hZOhGZIPo2ft2XpfONyCEwwIQMhs5PEaE=).

Forward Looking Statements

This press release contains forward-looking statements including statements related to our overall strategy prospects, potential and expected results, including statements about the timing of advancing omadacycline studies, the timing of enrollment in our clinical studies and our reporting of the results of such studies, the p an empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, UTI, and other bacteria concern, the prospect of omadacycline providing broad-spectrum activity, and our ability to obtain regulatory statements, other than statements of historical facts, included in this press release are forward-looking stat such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and otl meaning. These forward-looking statements are based upon our current expectations and involve substantia actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our f should not place undue reliance on these forward-looking statements. Our actual results and the timing of e those included in such forward-looking statements as a result of these risks and uncertainties. These and ot "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2016, and and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any for herein.

CONTACTS:

Media Relations:
Michael Lampe
(484) 575-5040
michael@scientpr.com (mailto:michael@scientpr.com)

Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
(212) 915-2568

PARATEK (https://www.globenewswire.com/NewsRoom/AttachmentNg/004d3d9f-8cdc-44bc-82d

Paratek Pharmaceuticals